Specific DNA methylation sites on the dopamine transporter gene differed between cannabis-dependent people and controls | Research

The takeaway

While overall methylation of the dopamine transporter gene promoter did not differ between 201 cannabis-dependent patients and 285 controls, specific methylation sites bound by key transcription factors showed significant differences.

Addiction genetics researchers, epigeneticists, and neuroscientists studying dopamine in substance use.

Specific CpG sites at SP1, p53, PAX5, GR binding sites differed

What the researchers found

No overall difference in DAT1 gene promoter methylation was found between groups. However, individual CpG sites showed significant methylation differences, particularly at sites bound by transcription factors involved in nervous system development (SP1, p53, PAX5, GR).

Why it matters

The dopamine transporter is central to reward and addiction. Finding that specific methylation sites differ in cannabis-dependent individuals could help explain why some people are more vulnerable to cannabis dependence.

The numbers in context

201 cannabis-dependent patients, 285 matched controls. Significant differences at individual CpG sites bound by SP1, p53, PAX5, and GR transcription factors.

How the study worked

Case-control study comparing DNA methylation patterns in the DAT1 gene promoter between 201 cannabis-dependent patients and 285 age- and sex-matched healthy controls. DNA was extracted from peripheral blood, bisulfite-converted, and sequenced.

What this study cannot tell us

Cross-sectional design cannot determine whether methylation differences preceded or resulted from cannabis dependence. Blood cell methylation may not perfectly reflect brain methylation. The clinical significance of the specific CpG site differences is unknown.

How to read the evidence

Moderate: adequate sample size with matched controls, though cross-sectional design and peripheral blood measurements.

When this study was published

Published in 2020 in Brain Sciences.

The bigger picture

Epigenetic modifications like DNA methylation represent a mechanism by which environmental exposures (including drug use) can alter gene expression without changing the DNA sequence, potentially contributing to or resulting from addiction.

Questions still open

Do these methylation changes occur before or after cannabis dependence develops? Could methylation patterns serve as biomarkers for dependence vulnerability? Do the affected transcription factor binding sites actually alter dopamine transporter expression?

Common questions

What is DNA methylation?

DNA methylation is a chemical modification that can turn genes on or off without changing the genetic code. It is one way that environmental factors, including drug use, can influence how genes function.

Does this mean cannabis dependence is genetic?

Not exactly. The study found epigenetic (not genetic) differences, meaning the DNA sequence was the same but how it was read differed. These changes could be a cause or consequence of cannabis dependence, and environmental factors play a role alongside genetics.

Read the original research

Contribution of Dopamine Transporter Gene Methylation Status to Cannabis Dependency.

Brain sciences, 10(6)

View on PubMed ↗Publisher’s paper ↗

Citation

Grzywacz, Anna; Barczak, Wojciech; Chmielowiec, Jolanta; Chmielowiec, Krzysztof; Suchanecka, Aleksandra; Trybek, Grzegorz; Masiak, Jolanta; Jagielski, Paweł; Grocholewicz, Katarzyna; Rubiś, Blazej. (2020). Contribution of Dopamine Transporter Gene Methylation Status to Cannabis Dependency.. Brain sciences, 10(6). https://doi.org/10.3390/brainsci10060400